Capsazepine Found to Shrink Oral Tumors
the Cancer Therapy Advisor take:
Each year approximately 40,000 patients in the United States are diagnosed with oral squamous cell carcinoma, which is the eighth most common cancer, and the disease will cause 8,000 deaths annually.
About 60% of patients have large tumors before they seek medical help, which results in a 30% survival rate 5 years after diagnosis. According to a study published in Oral Oncology, capsazepine has been shown to shrink oral cancers without harming healthy surrounding tissue. First author Cara B. Gonzales, DDS, PhD, and researchers at the School of Dentistry and School of Medicine at The University of Texas Health Science Center developed capsazepine as an agent to block TRPV1, which is a calcium channel in neurons. TRPV1 sends pain signals to the brain when stimulated.
Since capsazepine hinders tumor-secreted factors from stimulating TRPV1k , researchers believed the agent could reduce oral cancer pain. After they conducted their study, researchers found that capsazepine demonstrated anti-cancer activity as well, which may be linked to its capacity to increase oxidative tumor damage.
Researchers suspect that enhanced oxidative stress created by capsazepine causes apoptosis, or cell death, in tumor cells. Gonzales said the next step is to test how the new therapy fares against metastatic disease.
Mouse models treated with an agent called capsazepine showed dramatic tumor shrinkage.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed